نتائج البحث

Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report.

• Authors : Kumar V; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC, 27599-7305, USA.

Subjects: Waldenstrom Macroglobulinemia*/Waldenstrom Macroglobulinemia*/Waldenstrom Macroglobulinemia*/complications ; Waldenstrom Macroglobulinemia*/Waldenstrom Macroglobulinemia*/Waldenstrom Macroglobulinemia*/drug therapy ; Red-Cell Aplasia, Pure*/Red-Cell Aplasia, Pure*/Red-Cell Aplasia, Pure*/chemically induced

• Source: Journal of medical case reports [J Med Case Rep] 2023 May 28; Vol. 17 (1), pp. 220. Date of Electronic Publication: 2023 May 28.Publisher: BioMed Central Country of Publication: England NLM ID: 101293382 Publication Model: Electronic Cited Medium: Internet ISSN: 1752-1947

تفاصيل العنوان

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

• Source: Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node MalignancyBerndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, Nieters

تفاصيل العنوان

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

• Authors : National Cancer Institute (NCI)

• Source: Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function

تفاصيل العنوان

Epcoritamab in Previously Treated WM

• Authors : Genmab; Gottfried von Keudell, MD PhD, Sponsor Investigator

• Source: A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)

تفاصيل العنوان

Targets for Ibrutinib Beyond B Cell Malignancies.

• Authors : Berglöf A; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Hamasy A

Subjects: Lymphoproliferative Disorders/Lymphoproliferative Disorders/Lymphoproliferative Disorders/*drug therapy ; Osteoclasts/Osteoclasts/Osteoclasts/*drug effects ; Protein-Tyrosine Kinases/Protein-Tyrosine Kinases/Protein-Tyrosine Kinases/*antagonists & inhibitors

• Source: Scandinavian journal of immunology [Scand J Immunol] 2015 Sep; Vol. 82 (3), pp. 208-17.Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0323767 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia.

• Authors : Büyükkurt, Nurhilal¹ ; Soydaş, Barış²

• Source: Turkish Journal of Hematology. 2023, Vol. 40 Issue 2, p141-142. 2p.

تفاصيل العنوان

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

• Authors : Sobi, Inc.; Shayna Sarosiek, MD, Sponsor-Investigator

• Source: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

تفاصيل العنوان

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

• Authors : AstraZeneca; National Cancer Institute (NCI); Jonathon Cohen, Principal Investigator

• Source: An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients with Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

تفاصيل العنوان

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia.

• Authors : Wanlu Ma¹; Jiawei Zhao²; Lu Zhang³

• Source: Turkish Journal of Hematology. 2021, Vol. 38 Issue 1, p87-89. 3p.

تفاصيل العنوان

Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature.

• Authors : Rezania K; Department of Neurology, University of Chicago Medical Center, Chicago, IL 60637, USA. ; Soliven B

Subjects: Lymphoma/Lymphoma/Lymphoma/*complications ; Lymphoproliferative Disorders/Lymphoproliferative Disorders/Lymphoproliferative Disorders/*complications ; Myasthenia Gravis/Myasthenia Gravis/Myasthenia Gravis/*etiology

• Source: Leukemia & lymphoma [Leuk Lymphoma] 2012 Mar; Vol. 53 (3), pp. 371-80. Date of Electronic Publication: 2011 Sep 29.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان